DK1673063T3 - Transdermal farmaceutisk sammensætning - Google Patents

Transdermal farmaceutisk sammensætning

Info

Publication number: DK1673063T3
Authority: DK; Denmark
Prior art keywords: transdermal; pharmaceutical composition; transdermal pharmaceutical; trioleate; glyceryl
Prior art date: 2003-10-09

Application number

DK04769091T

Other languages

English (en)

Inventor

Istvan Eros

Csoka Ildiko Pannonhalmine

Csanyi Erzsebet Soosn

Attila Bodis

Erzsebet Lapis

Czinege Erzsebet Francsicsne

Csikos Emoke Kissne

Janos Illes

Original Assignee

Richter Gedeon Vegyeszet

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-09

Filing date

2004-10-06

Publication date

2008-05-19

2004-10-06 Application filed by Richter Gedeon Vegyeszet filed Critical Richter Gedeon Vegyeszet

2008-05-19 Application granted granted Critical

2008-05-19 Publication of DK1673063T3 publication Critical patent/DK1673063T3/da

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 6
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 2
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 abstract 2
229940074928 isopropyl myristate Drugs 0.000 abstract 2
239000004973 liquid crystal related substance Substances 0.000 abstract 2
229960004063 propylene glycol Drugs 0.000 abstract 2
235000013772 propylene glycol Nutrition 0.000 abstract 2
229940117972 triolein Drugs 0.000 abstract 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 1
239000002537 cosmetic Substances 0.000 abstract 1
229940011871 estrogen Drugs 0.000 abstract 1
239000000262 estrogen Substances 0.000 abstract 1
230000035876 healing Effects 0.000 abstract 1
238000002657 hormone replacement therapy Methods 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000000583 progesterone congener Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Diabetes (AREA)
Dispersion Chemistry (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Reproductive Health (AREA)
Otolaryngology (AREA)
Gynecology & Obstetrics (AREA)
Tropical Medicine & Parasitology (AREA)
Vascular Medicine (AREA)
Anesthesiology (AREA)

DK04769091T 2003-10-09 2004-10-06 Transdermal farmaceutisk sammensætning DK1673063T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU0303313A HUP0303313A2 (hu)	2003-10-09	2003-10-09	Transzdermális gyógyszerkészítmények
PCT/HU2004/000092 WO2005032514A1 (en)	2003-10-09	2004-10-06	Transdermal pharmaceutical composition

Publications (1)

Publication Number	Publication Date
DK1673063T3 true DK1673063T3 (da)	2008-05-19

Family

ID=90001702

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04769091T DK1673063T3 (da)	2003-10-09	2004-10-06	Transdermal farmaceutisk sammensætning

Country Status (13)

Country	Link
US (1)	US7728042B2 (da)
EP (1)	EP1673063B1 (da)
JP (1)	JP4884223B2 (da)
AT (1)	ATE383849T1 (da)
DE (1)	DE602004011374T2 (da)
DK (1)	DK1673063T3 (da)
EA (1)	EA009900B1 (da)
ES (1)	ES2300820T3 (da)
HU (1)	HUP0303313A2 (da)
NO (1)	NO20062053L (da)
PL (1)	PL1673063T3 (da)
RS (2)	RS51764B (da)
WO (1)	WO2005032514A1 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050238672A1 (en) *	2004-04-27	2005-10-27	Nimni Marcel E	Antifungal drug delivery
US20090075860A1 (en) *	2005-04-28	2009-03-19	Japan Science And Technology Agency	Transdermal absorption enhancer
FR2900575B1 (fr) *	2006-05-05	2008-10-17	Anteis Sa	Gel biocompatible a liberation controlee, son procede de preparation et son utilisation
HUP0700828A2 (en) *	2007-12-20	2010-01-28	Richter Gedeon Nyrt	Transdermal pharmaceutical compositions containing tolperisone alone and in combination
ES2326721B1 (es) *	2008-01-04	2010-07-16	Endor Nanotechnologies, S.L.	Conjugado de acido hialuronico para el tratamiento cosmetico y procedimiento de preparacion.
WO2010069519A1 (en) *	2008-12-18	2010-06-24	Merz Pharma Gmbh & Co. Kgaa	Topical compositions comprising at least one active ingredient poorly soluble in water and biopolymers such as hyaluronic acid with a pka-value between 5-7
US20110033515A1 (en) *	2009-08-04	2011-02-10	Rst Implanted Cell Technology	Tissue contacting material
PL2542241T3 (pl) *	2010-03-02	2016-12-30		Sposoby i kompozycje do leczenia lub zapobiegania objawom wahań hormonalnych
US8461102B2 (en)	2010-03-02	2013-06-11	George E. Royster, JR.	Methods and compositions for treating and preventing symptoms of hormonal variations
MX2013001858A (es)	2010-08-18	2013-09-13	Del Mar Pharmaceuticals	Composiciones y métodos para mejorar el beneficio terapéutico de los compuestos quimicos administrados de manera suboptima que incluyen hexitoles substituidos tal como dianhidrogalactitol y diacetildianhidrogalactitol.
US9114258B2 (en) *	2011-01-04	2015-08-25	Kato Medical Systems Llc	Electrokinetic nerve stimulator
AU2012389562A1 (en)	2011-08-17	2014-07-24	Dennis Brown	Compositions and methods to improve the therapeutic benefit of subotimally administered chemical compounds including substituted hexitols such as dibromodulcitol
EP3936133A1 (en)	2011-11-23	2022-01-12	TherapeuticsMD, Inc.	Natural combination hormone replacement formulations and therapies
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
SG11201404216TA (en)	2012-01-20	2014-08-28	Dennis Brown	Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
US9814693B2 (en)	2012-05-09	2017-11-14	Delmar Pharmaceuticals, Inc.	Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
KR102427777B1 (ko)	2012-06-26	2022-08-01	델 마 파마슈티컬스	디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법
CN104736176B (zh) *	2012-08-24	2017-10-13	英特格拉斯疗法有限公司	用于增强治疗剂透皮递送的化学组合物和方法
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
HU230989B1 (hu) *	2013-01-17	2019-08-28	Gd Photonics Kft.	Készítmény az UVB-fényterápia hatékonyságának fokozására, eljárás annak előállítására és alkalmazása
JP2016519684A (ja)	2013-04-08	2016-07-07	デニスエムブラウン	準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
WO2014175302A1 (ja) *	2013-04-24	2014-10-30	あすか製薬株式会社	無定形レボノルゲストレル、固体分散体及びそれらの製造方法
US9993460B2 (en)	2013-07-26	2018-06-12	Race Oncology Ltd.	Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
JP6783224B2 (ja)	2014-04-04	2020-11-11	デルマーファーマシューティカルズ	肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用
US10206932B2 (en)	2014-05-22	2019-02-19	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
AU2015296609A1 (en)	2014-07-29	2016-12-22	Therapeuticsmd, Inc.	Transdermal cream
CN104725370B (zh) *	2015-03-19	2017-03-01	天津大学	一种长春西汀管状晶体及制备方法
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
EP3435977A4 (en)	2016-04-01	2019-10-16	Therapeuticsmd, Inc.	PHARMACEUTICAL COMPOSITION OF STEROID HORMONE
WO2017173044A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Steroid hormone compositions in medium chain oils
CN109091451B (zh) *	2018-09-10	2021-08-13	武汉百纳礼康生物制药有限公司	亲水性药物的油相液晶凝胶前体制剂及其制备方法
RU2712918C1 (ru) *	2019-08-01	2020-02-03	Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации	Способ предотвращения острой боли при выполнении химического плевродеза после радикальных торакопластических операций онкологического характера
CN112426403B (zh) *	2020-12-09	2021-09-17	南京天纵易康生物科技股份有限公司	一种口腔溃疡凝胶及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4968539A (en) *	1987-12-01	1990-11-06	Lion Corporation	Liquid crystal membrane
US6458774B1 (en) *	1989-02-24	2002-10-01	Richter Gedeon Vegyeszeti Gyar Rt.	Compositions containing hyaluronic acid associates and a process for preparing same
CA1340994C (en) *	1989-09-21	2000-05-16	Rudolf Edgar Dr. Falk	Treatment of conditions and disease
IT1248666B (it) *	1990-05-30	1995-01-26	Fidia Spa	Gel in forma di film autosupportanti altamente idrati, processo per laloro preparazione e impiego nella terapia di lesioni e/o patologie cutanee
HU209605B (en) *	1991-04-15	1994-09-28	Chinoin Gyogyszer Es Vegyeszet	Process for production of wather-free transdermal preparation
US5326566A (en) *	1991-05-17	1994-07-05	Bristol-Myers Squibb Company	Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
TW218849B (da) *	1991-05-17	1994-01-11	Bristol Myers Squibb Co
US5616568A (en) *	1993-11-30	1997-04-01	The Research Foundation Of State University Of New York	Functionalized derivatives of hyaluronic acid
DE60233217D1 (de) *	2001-05-01	2009-09-17	Corium Internat Inc	Hydrogel-zusammensetzungen
CA2448273C (en) *	2001-05-23	2010-06-29	Christian Franz Holinka	Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
JP2003063996A (ja) *	2001-08-23	2003-03-05	禎秀 ▲廣▼▲崎▼	皮膚外用剤
US6960563B2 (en) *	2001-08-31	2005-11-01	Morton Grove Pharmaceuticals, Inc.	Spontaneous emulsions containing cyclosporine

2003
- 2003-10-09 HU HU0303313A patent/HUP0303313A2/hu unknown
2004
- 2004-10-06 WO PCT/HU2004/000092 patent/WO2005032514A1/en active IP Right Grant
- 2004-10-06 US US10/575,145 patent/US7728042B2/en not_active Expired - Fee Related
- 2004-10-06 EA EA200600750A patent/EA009900B1/ru not_active IP Right Cessation
- 2004-10-06 EP EP04769091A patent/EP1673063B1/en not_active Expired - Lifetime
- 2004-10-06 PL PL04769091T patent/PL1673063T3/pl unknown
- 2004-10-06 RS RS20060249A patent/RS51764B/en unknown
- 2004-10-06 AT AT04769091T patent/ATE383849T1/de active
- 2004-10-06 DK DK04769091T patent/DK1673063T3/da active
- 2004-10-06 ES ES04769091T patent/ES2300820T3/es not_active Expired - Lifetime
- 2004-10-06 RS YUP-2006/0249A patent/RS20060249A/sr unknown
- 2004-10-06 DE DE602004011374T patent/DE602004011374T2/de not_active Expired - Lifetime
- 2004-10-06 JP JP2006530614A patent/JP4884223B2/ja not_active Expired - Fee Related
2006
- 2006-05-08 NO NO20062053A patent/NO20062053L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
DE602004011374T2 (de)	2009-01-08
ATE383849T1 (de)	2008-02-15
EA009900B1 (ru)	2008-04-28
RS51764B (en)	2011-12-31
RS20060249A (en)	2008-06-05
US7728042B2 (en)	2010-06-01
ES2300820T3 (es)	2008-06-16
US20070264345A1 (en)	2007-11-15
DE602004011374D1 (de)	2008-03-06
HUP0303313D0 (en)	2003-12-29
JP4884223B2 (ja)	2012-02-29
EP1673063B1 (en)	2008-01-16
EA200600750A1 (ru)	2006-08-25
WO2005032514A1 (en)	2005-04-14
EP1673063A1 (en)	2006-06-28
HUP0303313A2 (hu)	2005-07-28
JP2007508287A (ja)	2007-04-05
PL1673063T3 (pl)	2008-06-30
NO20062053L (no)	2006-05-08

Publication	Publication Date	Title
DK1673063T3 (da)	2008-05-19	Transdermal farmaceutisk sammensætning
IL154888A (en)	2013-12-31	Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
HK1140377A1 (en)	2010-10-15	Pharmaceutical use of substituted amides
MXPA05004404A (es)	2006-02-10	Composicion topica para cuidado de la piel.
SG151329A1 (en)	2009-04-30	Amido compounds and their use as pharmaceuticals
EA200801492A1 (ru)	2008-10-30	Фармацевтическое применение замещенных амидов
SG163518A1 (en)	2010-08-30	Amido compounds and their use as pharmaceuticals
TW200626156A (en)	2006-08-01	Amido compounds and their use as pharmaceuticals
BR0108173A (pt)	2003-01-21	Composições farmacêuticas de toxina de botulina
HK1108350A1 (en)	2008-05-09	Cooling topical patch preparation
TW200605870A (en)	2006-02-16	Topical methadone compositions and methods for using the same
EA200970841A1 (ru)	2010-04-30	Фармацевтическое применение замещенных амидов
SG161261A1 (en)	2010-05-27	Lactam compounds and their use as pharmaceuticals
EA200801243A1 (ru)	2008-10-30	Фармацевтическое применение замещенных амидов
ATE361084T1 (de)	2007-05-15	Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
SE0101387D0 (sv)	2001-04-20	Novel compounds
BRPI0620431A8 (pt)	2018-01-09	uso de um poliuretano formador de película, preparação farmacêutica líquida, aplicador e emplastro contendo a referida preparação farmacêutica
ID27503A (id)	2001-04-12	Tts yang mengandung antioksidan
MXPA02007059A (es)	2004-08-11	Composicion de autobronceado que contiene un ester n-acilado de aminoacido y un agente de autobronceado.
DE602005021770D1 (de)	2010-07-22	Indol-1-yl-essigsäurederivate
AU2003296692A1 (en)	2005-01-21	Lipidic protein-transfer systems and cosmetic/dermatological use thereof
TNSN07203A1 (en)	2008-11-21	Pharmaceutical compositions for the treatment of cellulite
DE60312969D1 (de)	2007-05-16	Zubereitung für die wundheilung und zur verhinderung des anhaftens von verbänden an die wunde
AU2003292326A1 (en)	2004-06-03	Cosmetic or pharmaceutical composition comprising peptides with the sequence arg-gly-ser
FR2856297B1 (fr)	2005-08-05	Utilisation de (2s,3r,4s)-4-hydroxyisoleucine dans des compositions cosmetiques pour application topique